GlassScriptPhysician profile
April L Green
NPI 1194076836
$1,462.83
in general payments reported to CMS, 2019-2025
33 companies · $16.95 in 2025
The $16.95 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $757 · 2022: $529 · 2023: $125 · 2024: $35.07 · 2025: $16.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $176.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $194.41 | 2021-2023 | Jakafi |
| Pharmacyclics LLC, An Abbvie Company | $114.31 | 2021-2022 | |
| Celgene Corporation | $88.58 | 2021 | |
| Blueprint Medicines Corporation | $84.80 | 2021-2022 | |
| Emmaus Medical, INC. | $84.73 | 2021-2022 | |
| Amgen INC. | $76.26 | 2021-2022 | |
| Genzyme Corporation | $68.81 | 2022 | |
| Novartis Pharmaceuticals Corporation | $62.06 | 2021-2022 | |
| Dova Pharmaceuticals | $61.25 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $57.52 | 2021-2022 | |
| Astellas Pharma US INC | $42.61 | 2021-2023 | Cresemba |
| Ipsen Biopharmaceuticals, INC | $39.86 | 2021 | |
| Merck Sharp & Dohme LLC | $37.20 | 2021-2022 | |
| Abbvie INC. | $35.07 | 2024 | |
| Janssen Biotech, INC. | $34.56 | 2023 | Darzalex, Tecvayli |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $30.90 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.66 | 2022-2023 | Iclusig |
| Glaxosmithkline, LLC. | $29.92 | 2021-2022 | |
| Rigel Pharmaceuticals, INC. | $29.83 | 2021 | |
| Eisai INC. | $29.52 | 2021-2022 | |
| Adaptive Biotechnologies Corporation | $28.41 | 2023 | Clonoseq |
| Kite Pharma, INC. | $27.86 | 2022 | |
| Servier Pharmaceuticals LLC | $26.85 | 2021-2022 | |
| Myovant Sciences INC. | $20.03 | 2021 | |
| Karyopharm Therapeutics INC. | $18.58 | 2022 | |
| Abbott Laboratories | $16.95 | 2025 | Freestyle Libre 3 |
| Pharmacosmos Therapeutics INC. | $16.95 | 2021 | |
| Apellis Pharmaceuticals, INC. | $13.36 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $12.73 | 2021 | |
| Secura Bio, INC. | $12.25 | 2022 | |
| Tersera Therapeutics LLC | $12.11 | 2021 | |
| Alexion Pharmaceuticals, INC. | $12.08 | 2021 | |
| Acceleron Pharma, INC. | $11.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.